Following a query from one of their colleagues, the authors felt that figure 2 was misleading with respect to the role of preferential PDE4B inhibition on cellular cAMP levels and downstream signalling in the inflammatory and fibrotic pathways, and wished to amend the figure. The amended version of figure 2 is shown below.

The article has been corrected and republished online.

Hypothesised role of pan-phosphodiesterase 4 (PDE4)/PDE4B inhibition in treating lung fibrosis. Dotted lines indicate hypothesised role of PDE4B preferential inhibition in increasing cAMP levels and thereby allowing inhibition of a) inflammatory processes and b) fibroblast activation. ECM: extracellular matrix; EPAC1/2: exchange protein directly activated by cAMP 1/2; GPCR: G protein-coupled receptor; PKA: protein kinase A.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissionsersnet.org